Figure 3.

The immunogenicity and anti-tumor activity of 25 short mutated peptides. DCs were pulsed with one of these 25 mutated peptides. Groups (8–10 mice per group) were immunized twice with each peptide-pulsed DC vaccine (1 × 10⁶) at a 2-week interval. Three or four mice were used for immunogenicity assessment (A), and 5–6 mice were used for the LLC1 cells challenge (B). IFN-γ production in response to immunized peptide and LLC1 cells was evaluated. In addition, tumor growth was measured after LLC1 cells (1 × 10⁶) were challenged in these immunized mice.